Juno Therapeutics, a Bristol-Myers Squibb company, was granted FDA orphan designation for lisocabtagene maraleucel as a treatment of splenic marginal zone lymphoma, according to a post to the agency’s website. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMY:
- Bristol-Myers granted three applications for myeloma candidate Abecma
- MRK vs. BMY: Which Pharmaceutical Stock is Better?
- Bristol-Myers announces CHMP opinion recommending approval for Breyanzi
- Juno Therapeutics’ lisocabtagene maraleucel receives FDA orphan designation
- Bristol-Myers announces three-year follow-up results from CheckMate-816 study